March 20, 2026   |   Read online Early AI Diagnostics Spotlight: See Why (CODX) Just Hit This Morning's Watchlist Any content you receive is for information purposes only. Always conduct your own research. *Sponsored Daily Edge Report Puts Co-Diagnostics, Inc. (NASDAQ: CODX) At The Top Of This Morning's Watchlist—Friday, March 20, 2026 Don't miss the next breakout — get real-time alerts sent straight to your phone! Get Ready Now—Full Coverage Is Starting Now Consider Starting Your Own Research On (CODX) This Morning… [Company Website] March 20, 2026 Early AI Diagnostics Spotlight | See Why (CODX) Just Hit This Morning's Watchlist Dear Reader, Most diagnostic systems people rely on today were built for a different era. They often require centralized labs, specialized equipment, and turnaround times that can stretch from hours to days. In fast-moving environments, whether it's public health response, clinical decision-making, or decentralized testing, those delays can matter. But that model has been steadily evolving. Across healthcare systems, research labs, and point-of-care settings, there's increasing demand for faster, more flexible diagnostic tools that can deliver accurate results without the traditional bottlenecks of lab-based workflows. That's where a new generation of molecular diagnostics is starting to take shape. And one company operating within that shift is Co-Diagnostics, Inc. (NASDAQ: CODX). (CODX) is focused on developing PCR-based diagnostic technologies designed to be faster, more adaptable, and less dependent on complex infrastructure. Its proprietary CoPrimer™ platform aims to improve test accuracy while reducing issues like cross-reactivity—an ongoing challenge in molecular testing. According to the company, this technology has been used to develop assays for infectious diseases including CO-VID-19, tuberculosis, and other pathogens. But the story isn't just about the technology. (CODX)'s structure adds another layer to the setup. The public float remains limited, with just under 2M shares listed as available to the public. When companies have small floats like this, the potential exists for big swings if demand begins to shift. A small group of firms, including HC Wainwright, Maxim Group, and D. Boral Capital, have initiated or maintained coverage on (CODX), with recent targets generally falling in the $1.50 to $3.00 range. Representing a potential upside from 30% to over 2,000% from recent levels.  Also, (CODX) recently surged approximately 108% in a single session, moving from around $2.11 on March 9 to $4.40 the following day. Taken together, these elements place (CODX) at an interesting intersection of decentralized diagnostics, molecular innovation, and evolving global testing demand. And that's part of the reason (CODX) is topping our watchlist this morning—Friday, March 20, 2026. A New Approach to Rapid, Decentralized Diagnostics Co-Diagnostics, Inc. (NASDAQ: CODX) is a molecular diagnostics company focused on developing and commercializing technologies that detect diseases by analyzing genetic material such as DNA and RNA. The company designs, manufactures, and markets diagnostic tests and related reagents used in healthcare, research, and public health settings worldwide. At the core of its business is polymerase chain reaction (PCR) testing, widely considered the gold standard for identifying infectious diseases. Co-Diagnostics' proprietary CoPrimer™ technology is designed to improve the accuracy and specificity of these tests by reducing false signals and enabling more precise detection of pathogens. Building on this foundation, the company has introduced its Premier™ AI platform, which integrates artificial intelligence into the assay design process. This system is intended to accelerate the development of diagnostic tests by rapidly analyzing genetic sequences and optimizing primer design, allowing the company to respond more quickly to emerging pathogens and evolving variants. The company's product ecosystem is built around its Co-Dx PCR platform, which is being developed for both point-of-care and at-home use. This system combines a portable diagnostic instrument, test collection kits, and a mobile-connected interface to deliver results in roughly 30 minutes without the need for traditional lab infrastructure . The goal is to bring high-quality molecular diagnostics closer to patients, enabling faster decision-making in clinical and non-clinical environments. (CODX) has developed and distributed PCR-based tests targeting a wide range of conditions, including CO-VID-19, influenza, tuberculosis, hepatitis, HPV, and other infectious diseases, as well as applications in agriculture and vector-borne disease monitoring . Beyond infectious disease, the company is also exploring genetic testing and broader applications of its technology platform. Taken together, Co-Diagnostics is positioning itself within a growing shift toward AI-enabled, decentralized diagnostics, where faster development cycles and point-of-care accessibility are becoming increasingly important. Expanding Access Across a Decentralized U.S. Testing Market The U.S. diagnostic landscape is shifting toward faster, decentralized testing, and (CODX) is positioning its platform to operate across multiple high-volume healthcare channels, from physician offices to pharmacies and in-home care. In traditional settings alone, the scale is significant. There are approximately 843,187 active physicians in the U.S., supporting an estimated 500M patient visits annually, with pediatric utilization particularly high, around 95% of children visit a physician each year . These interactions represent recurring potential for rapid diagnostic tools, especially in cases where "test-to-prescribe" workflows can streamline care decisions. Beyond traditional practices, urgent care centers, totaling roughly 14,223 nationwide, continue to expand as convenient, front-line healthcare access points. At the same time, the U.S. retail pharmacy footprint exceeds 61,715 locations, many of which already conduct in-house testing using antigen-based methods, highlighting an existing infrastructure that could transition toward more advanced molecular diagnostics. Skilled nursing facilities represent another key segment, with over 15,000 facilities serving approximately 1.3M residents annually, where rapid infectious disease detection can play a critical role in outbreak prevention and patient management. At the consumer level, accessibility continues to improve. Approximately 88.9% of the U.S. population lives within 5 miles of a pharmacy, reinforcing the potential for widespread, community-based testing without requiring a traditional doctor visit. (CODX)'s platform is designed to align with this shift. Its upper respiratory multiplex testing capabilities, including detection of illnesses like influenza and RSV, aim to decentralize testing away from centralized labs and into point-of-care or at-home environments. With results delivered in approximately 30 minutes and costs positioned to be comparable to a typical co-pay, the model supports faster clinical decisions while reducing friction for both providers and patients. Taken together, these segments represent a multi-channel, high-frequency testing market, where speed, accessibility, and cost efficiency are becoming increasingly important, and where decentralized molecular diagnostics platforms like (CODX) may have room to expand. Momentum Building Across Platform, Partnerships, and Market Positioning Recent announcements from Co-Diagnostics, Inc. (NASDAQ: CODX) highlight continued progress across its technology platform, global expansion efforts, and capital markets positioning as the company moves through early 2026. The company has recently strengthened its intellectual property portfolio with the granting of a Japanese patent (No. 7797537) covering elements of its Co-Dx PCR platform. This development reinforces global protection of its core diagnostic technologies and supports broader international expansion efforts. On the manufacturing front, (CODX)'s joint venture, CoSara Diagnostics, has achieved key operational milestones, including regulatory licensing to manufacture PCR instruments and ISO 13485 certification. These steps support the company's ability to scale production and align with its longer-term commercialization strategy. From a regulatory and development standpoint, (CODX) continues to advance its Co-Dx PCR point-of-care platform, which remains under review by regulatory bodies such as the FDA. The company has indicated ongoing clinical performance studies and regulatory pathways as it works toward bringing the platform to market. The company has historically maintained a strong ca-sh position with no long-term debt, which is important for a development-stage diagnostics company. As of recent filings, (CODX) reported tens-of-mils in ca-sh and equivalents, giving it runway to continue platform development and regulatory efforts. Financial Position & Leadership Strategically, Co-Diagnostics, Inc. (Nasdaq: CODX) has focused on leveraging non-dilutive funding to support its research and development efforts. The company has secured millions in grant funding from the Bill & Melinda Gates Foundation, including a recent $8.9M award aimed at advancing accessible tuberculosis diagnostics. These grants help validate the platform's clinical potential while providing additional financial support as the company progresses through the FDA 510(k) clearance pathway. As of late 2025, (CODX) reported a preliminary ca-sh balance of approximately $11.9M, providing capital to continue advancing its core clinical and regulatory objectives. Leadership remains a consistent element of the company's strategy. Founder and CEO Dwight Egan, who has led the company for over 12 years, continues to emphasize a disciplined growth approach focused on regulatory milestones and commercialization of its point-of-care PCR platform. Under his leadership, the company has navigated the volatility of the pandemic period while shifting toward a more diversified diagnostics model. At the same time, (CODX) is expanding into artificial intelligence through a newly established AI-focused business unit. This initiative is designed to improve operational efficiency and accelerate assay development timelines, potentially reducing time-to-market for future diagnostic tests. 8 Reasons Why (CODX) Is Topping Our Watchlist This Morning — Friday, March 20, 2026 1. Low Float Structure: With approximately just under 2M shares in the public float, (CODX) maintains a relatively tight structure. Lower float setups can sometimes lead to increased volatility if interest begins to build. 2. Positioned in a Shifting Diagnostics Market: Healthcare is moving toward faster, decentralized testing, with demand increasing for point-of-care and at-home diagnostics. (CODX) is developing a platform designed to operate within this shift, targeting faster turnaround times without traditional lab infrastructure. 3. Proprietary PCR Technology + CoPrimer™ Advantage: The company's CoPrimer™ technology is designed to improve test specificity and reduce cross-reactivity, two key challenges in molecular diagnostics, supporting more reliable detection across multiple pathogens. 4. AI-Driven Development Platform: (CODX) has introduced its Premier™ AI platform, aimed at accelerating assay design by analyzing genetic sequences and optimizing test development. This could allow faster response times to emerging diseases and variants. 5. Large Addressable U.S. Testing Market: The company's platform targets a broad market across physician offices, urgent care centers (14,223), pharmacies (61,000+), and skilled nursing facilities (15,000+), representing hundreds of millions of annual patient interactions where rapid diagnostics may play a role. 6. Strengthening IP & Advancing Platform Development: Recent updates include a newly granted Japanese patent covering elements of its Co-Dx PCR platform, alongside continued development of its point-of-care system and multiplex respiratory testing capabilities. 7. Emerging Analyst Coverage: Analysts have initiated or maintained coverage, with recent targets ranging from the $1.50 to $3.00 range, implying a potential upside from 30% to over 2,000%. 8. Backed by Gates: with Gates Foundation support that includes a recent $8.9M award, (CODX) has secured outside funding tied to its tuberculosis testing work. Get (CODX) On Your Screen This Morning… When you step back and look at the full picture, (CODX) brings together several elements that are hard to overlook. A tightly held float, paired with a recent 108% move in less than 24 hours, highlights how quickly momentum can shift when attention builds. At the same time, its proprietary CoPrimer™ platform is designed to deliver fast, high-specificity PCR testing in a compact format, supported by a growing pipeline targeting multiple high-impact diagnostic areas. Layer in global patent protection across key regions, an expanding international footprint through its India-based joint venture, and backing from the Bill & Melinda Gates Foundation, including a recent $8.9M award, and the broader setup begins to take shape. We have all eyes on (CODX) this morning—Friday, March 20, 2026. Take a look at (CODX) while it's still early. Also, keep a lookout for our next update, it could be here before the bell rings. Sincerely, Joel Locke Senior Editor The Daily Edge Report DailyEdgeReport.com ("DailyEdgeReport" or "DER" ) is owned by GG Media Holdings LLC, a multi member limited liability company. Data is provided from third-party sources and DER is not responsible for its accuracy. Make sure to always do your own research and due diligence on any day and swing profile DER brings to your attention. Any emojis used do not have a specific defined meaning, and may be used inconsistently. We do not provide personalized in-vest-ment advice, are not in-vest-ment advisors, and any profiles we mention are not suitable for all in-vest-ors. Pursuant to an agreement between GG Media Holdings LLC and TD Media LLC, GG Media Holdings LLC has been hired for a period beginning on 03/19/2026 and ending on 03/20/2026 to publicly disseminate information about (CODX:US) via digital communications. Under this agreement, TD Media LLC has paid GG Media Holdings LLC seven thousand five hundred USD ("Funds"). These Funds were part of the seventy five thousand USD funds that TD Media LLC received from a third party named JRZ Capital LLC who did receive the Funds directly or indirectly from the Issuer and does not own stock in the Issuer but the reader should assume that the clients of the third party own shares in the Issuer, which they will liquidate at or near the time you receive this communication and has the potential to hurt share prices. Neither GG Media Holdings LLC, TD Media LLC and their member own shares of (CODX:US). Please see important disclosure information here: https://dailyedgereport.com/disclosure/codx-GguGM/#details   Update your email preferences or unsubscribe here © 2026 Daily Edge Report 1401 Pennsylvania Ave Suite 105 Wilmington, Delaware 19806, United States Terms of Service